• Inicio
  • Formações
  • Formação à Medida
  • News & Trends
  • Sobre nós
  • Contacto

Data Integrity and Compliance With Drug CGMP

FDA expects that all data be reliable and accurate (see the “Background” section). CGMP regulations and guidance allow for flexible and risk-based strategies to prevent and detect data integrity issues. Firms should implement meaningful and effective strategies to manage their data integrity risks based on their process understanding and knowledge management of technologies and business models 

 

Data Integrity and Compliance With Drug CGMP

 

 

News & Trends

Procurar

Recentes

  • FDA Biosimilar Development – Q&A Guidance: Q&As on Biosimilar Development and the BPCI Act
  • NDSG workplan 2026-2028 : Data and AI in medicines regulation
  • New guidance on the conduct of clinical trials during public health emergencies
  • Nova lei regula ensaios clínicos de medicamentos para uso humano em Portugal
  • FDA draft guidance :“New Clinical Investigation Exclusivity: 3-Year Exclusivity for Drug Products – Questions and Answers.”
  • webinar INTELIGÊNCIA ARTIFICIAL NA INDÚSTRIA FARMACÊUTICA :IA EM CONTEXTO GxP (Annex 11, 22, EU AI Act , GAMP®)
  • GESTÃO da DISPONIBILIDADE do MEDICAMENTO: “Formação muito útil !
  • IMDRF Playbook for Medical Device Regulatory Reliance Programs

91 257 00 03 (Chamada para a rede móvel nacional)
info@formiventos.com

  • Follow
  • CLIENTES & TESTIMONIALS
  • ASSOCIAÇÕES OFICIAIS
  • CERTIFICAÇÕES E CREDITAÇÕES
  • ADVISORY BOARD
  • Política de Privacidade
  • Contacto